Altimmune Inc ALT

US Biotechnology

$2.84 ▼ -4.70% ($-0.14)

⬇️ Below Yest. Low 🔥 High Short Interest 🗓️ Earnings Next Week

Open $2.99

Prev Close $2.98

Day Range $2.78 – $2.99

52W Range $2.56 – $6.44

Market Cap $552.31M

Beta 0.14

EPS (TTM) $-0.92

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2005-10-06
Shares Out.	194,470,000
Website	altimmune.com/ ↗
Phone	12406541450
Employees	57
Net Income	-$22.6M
Free Cash Flow	-$71.7M
Total Assets	$335.6M
Total Liabilities	$51.6M
Equity	$284.0M

About Altimmune Inc

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Altimmune Inc is a publicly traded company under the ticker symbol ALT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.